GLYSTALI

Welcome to the Brand page for “GLYSTALI”, which is offered here for Anti-inflammatories; antibacterial pharmaceuticals; cardiovascular pharmaceuticals; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for the treatment and prevention of hematalogic disorders and and in tissue and organ transplantation; pharmaceutical preparations for the treatment and prevention of eye diseases and conditions; pharmaceutical preparations for the treatment and prevention of heart rhythm disorders; pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of kidney diseases; pharmaceutical preparations for the treatment and prevention of hypertension; pharmaceutical preparations for the treatment and prevention of skin disorders; pharmaceutical preparations for the treatment and prevention of cancer and tumors; pharmaceutical preparations for the treatment and prevention of allergies; pharmaceutical preparations for the treatment and prevention of bone diseases; pharmaceutical preparations for the treatment and prevention of respiratory diseases and asthma; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use;.

Its status is currently believed to be active. Its class is unavailable. “GLYSTALI” is believed to be currently owned by “Zydus Pharmaceuticals (USA) Inc.”